![]() |
|
|
Vol. 300, Issue 3, 925-931, March 2002
Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan
| |
Abstract |
|---|
|
|
|---|
Irritable bowel syndrome (IBS) is a common disorder mainly characterized by altered bowel habits and visceral pain. In this study, we investigated the role of tachykinin NK1 receptors in the visceral pain response (abdominal muscle contraction) caused by colorectal distention in rabbits previously subjected to colonic irritation, using the selective tachykinin NK1 receptor antagonists TAK-637 [(aR,9R)-7-[3,5-Bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4] diazocino[2,1-g][1,7]naphthyridine-6,13-dione] and (±)-CP-99,994 (±)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine. Intracolorectal administration of 0.8% acetic acid solution enhanced the nociceptive response to colorectal distention, producing a significant increase in the number of abdominal muscle contractions. Under these conditions, intraduodenal TAK-637 (0.1-3 mg/kg) dose dependently decreased the number of distention-induced abdominal contractions, and a significant inhibitory effect was observed with doses of 0.3 to 3 mg/kg. Another tachykinin NK1 antagonist, (±)-CP-99,994, also reduced the number of abdominal contractions. In contrast, the enantiomer of TAK-637 (which has very weak tachykinin NK1 receptor antagonistic activity), trimebutine maleate, ondansetron, and atropine sulfate did not inhibit the abdominal response. The main metabolite of TAK-637, which has more potent tachykinin NK1 receptor antagonistic activity but permeates the central nervous system less well than TAK-637, produced less inhibition of the viscerosensory response. When given intrathecally, TAK-637 and (±)-CP-99,994 markedly reduced the number of abdominal contractions. These results suggest that tachykinin NK1 receptors play an important role in mediating visceral pain and that TAK-637 inhibits the viscerosensory response to colorectal distention by antagonizing tachykinin NK1 receptors, mainly in the spinal cord. They also suggest that TAK-637 may be useful in treating functional bowel disorders such as IBS.
| |
Introduction |
|---|
|
|
|---|
Chronic
visceral pain and/or discomfort are the most common symptoms observed
in patients with IBS (Naliboff et al., 1997
). Most patients show a
lowered threshold of nociceptive perception, i.e., hypersensitivity to
colorectal distention (Mertz et al., 1995
). Although the precise
mechanisms underlying the changes in visceral sensitivity are not fully
understood, recent studies suggest that some previous experiences, such
as gastrointestinal inflammation, psychological or emotional stress,
and surgery are associated with this dysfunction (Gwee et al., 1996
;
Accarino et al., 1997
). Central sensitization, including spinal
plasticity and/or hypersensitivity of the viscera, appears to occur in
IBS patients after stress or inflammation (Mayer and Gebhart, 1994
).
Among the several experimental models available for estimating visceral
pain, gastrointestinal distention with a balloon is one of the most
commonly used methods. The noxious visceral stimuli caused by
colorectal distention produce reflex responses such as abdominal
contractions or cardiovascular responses (Ness and Gebhart, 1988
).
These responses can be quantified and have been reported to correlate
with the intensity of the colorectal distention applied. Sensitivity to
distention has also been reported to increase after repeated stress,
intestinal inflammation caused by chemicals, or intestinal infection in
experimental animals (Gue et al., 1997
; McLean et al., 1997
; Al-Chaer
et al., 2000
).
SP is a member of the tachykinin family of peptides. There are three
distinct receptors for tachykinins, and tachykinin
NK1, NK2, and
NK3 receptors have high affinity for SP, NKA, and
NKB, respectively (Otsuka and Yoshioka, 1993
). SP has been identified in mammalian CNS tissues such as the brain and spinal cord, as well as
in the enteric nervous system of the gut (Holzer and Holzer-Petsche, 1997
; Quartara and Maggi, 1998
). Numerous reports have indicated that SP mediates efferent neuroneuronal and neuromuscular transmission in the enteric nervous system, resulting in the activation of gastrointestinal motility (Scheurer et al., 1994
). It also mediates the
transmission of afferent perceptional signals from the gastrointestinal tract via capsaicin-sensitive C-fibers (Gamse et al., 1980
), and there
is considerable evidence that SP in the spinal cord plays an important
role in mediating noxious stimuli from the peripheral organs (Chapman
and Dickenson, 1993
).
TAK-637
[(aR,9R)-7-[3,5-Bis(trifluoromethyl)benzyl]-8,9,10,11- tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione] is a new orally active tachykinin NK1
receptor antagonist with high affinity (IC50 = 0.45 nM) for tachykinin NK1 receptors in human
IM-9 cells, but with low affinity (IC50 = 85 nM)
for rat tachykinin NK1 receptors (Natsugari et
al., 1999
). It has been demonstrated that TAK-637 has high
selectivity for tachykinin NK1 receptors, and its
affinity for tachykinin NK2 and
NK3 receptors is at least 2000 times lower than
that for tachykinin NK1 receptors (Natsugari et
al., 1999
). (±)-CP-99,994 has a different chemical structure from
TAK-637 but is also a selective tachykinin NK1 receptor antagonist in humans (Desai et al., 1992
). Because there are
considerable interspecies differences between rats and humans in the
affinity of tachykinin NK1 receptors for these
antagonists (Beresford et al., 1991
), we carried out our investigations
in rabbits, which are highly responsive to TAK-637 and (±)-CP-99,994, i.e., both agents almost completely blocked the
(Sar9,Met(O2)11)-SP-induced
depressor response at 0.01 mg/kg, i.v. in rabbits, but not in rats,
even at 1 mg/kg, i.v.
The aim of this study was to clarify the possible role of tachykinin NK1 receptors in visceral perception by investigating the effects of TAK-637 and (±)-CP-99,994 on the viscerosensory response caused by colorectal distention. We also attempted to clarify whether TAK-637 acts peripherally or centrally.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Male New Zealand White/Kbl rabbits (Kitayama Rabesu, Ina, Japan) weighing 1 to 2.5 kg were used. Before the experiments, the animals were housed separately under standard controlled environmental conditions with a 12-h light/dark cycle and were given food and water ad libitum. Before the experiments, the animals were deprived of food for 48 h but allowed free access to water. The care and use of animals and experimental protocol of this study were approved by Takeda's Experimental Animal Care and Use Committee.
Drugs.
TAK-637, the enantiomer of TAK-637, the main
metabolite of TAK-637 (metabolite I; M-I), and (±)-CP-99,994 were all
synthesized at Takeda Chemical Industries, Ltd., Osaka, Japan.
Ondansetron was synthesized by Junsei Chemical Co., Osaka, Japan.
Atropine sulfate and
-cyclodextrin were purchased from Wako Pure
Chemicals, Osaka, Japan. Trimebutine maleate and buprenorphine
hydrochloride were obtained from Sigma Chemical Co. (St. Louis, MO) and
Diosynth (Apeldoorn, The Netherlands), respectively. Methylcellulose
and bupivacaine hydrochloride were purchased from Shinetsu Chemical Industries (Tokyo, Japan) and AstraZeneca (Osaka, Japan),
respectively. For intraduodenal administration, TAK-637,
trimebutine maleate, ondansetron, atropine sulfate, and buprenorphine
hydrochloride were suspended in 0.5% methylcellulose solution and
administered at a volume of 4 ml/kg. For i.v. administration,
(±)-CP-99,994 and buprenorphine hydrochloride were dissolved in saline
and administered at a volume of 2 ml/kg, whereas TAK-637 and M-I were
dissolved in dimethyl sulfoxide and administered at a volume of 0.05 ml/kg. For i.t. administration, TAK-637 was dissolved in 20%
-cyclodextrin solution, then lyophilized and stored until required.
For use, the lyophilized TAK-637 was dissolved in distilled water and
diluted with 20%
-cyclodextrin solution. (±)-CP-99,994 was
dissolved in saline.
Surgical Procedures. The abdomen was opened by a midline laparotomy under pentobarbital sodium (30 mg/kg, i.v.) anesthesia, and a silicone catheter (o.d., 1.5 mm; i.d., 1 mm) was inserted to allow intraduodenal administration. One end of the catheter was introduced into the duodenal lumen through an incision made 2 cm distal from the pyloric ring. The other end was run subcutaneously along the costal flank and out through an incision between the scapulae, where it was fixed to the adjacent skin with silk sutures.
For i.t. administration, the animals were anesthetized with pentobarbital and respiration was maintained at 60 breaths/minute by mechanical ventilation. A polyethylene intrathecal catheter (o.d., 0.66 mm; i.d., 0.28 mm) was chronically implanted into the T13-L2 spinal segments through a puncture in the atlanto-occipital membrane and was secured to the skull using the method of Yaksh and Rudy (1976)Colorectal Irritation.
After a 48-h fast, each animal was
placed into a clear plastic syringe (i.d., 13-15 cm; length, 45-60
cm; Osaka Riko, Osaka, Japan). To acclimatize the animals to this new
environment and the colorectal distention technique, colorectal
distention was performed twice before proceeding with colorectal
irritation. A 6-cm-long balloon made from the tip of a condom was
inserted through the anal canal and advanced 8 cm into the rectum, then the tube was secured to the base of the tail with tape. The balloon was
rapidly inflated with air to a pressure of 30 mm Hg, and this pressure
was maintained for 10 min. Colorectal irritation was performed
according to the method of Langlois et al. (1997)
with minor changes.
Acetic acid solution (0.8%, 4 ml, 24 ml/min) was applied to the
colorectal region through a silicone catheter (o.d., 3 mm; i.d., 2 mm)
inserted 2 to 8 cm in from the anal verge. One hour after introduction
of the acetic acid solution, the animals displayed a hypersensitive
response to colorectal distention as described by Plourde et al.
(1997)
.
Colorectal Distention Procedures. To count the abdominal contractions, the receiver for the wireless force transducer was connected to a polygraph system (WindGraf 980; Gould Inc., Cleveland, OH). Because colorectal sensitivity to colorectal distention after acetic acid treatment differed among the animals, the most appropriate distention pressure (i.e., one that produced more than 10 contractions/10 min) was selected by increasing in 5-mm Hg steps. Any animal that did not exhibit an adequate response after the pressure had been increased to 45 or 50 mm Hg was excluded from the study.
In the first series of experiments, we investigated whether treatment with acetic acid solution would enhance the response to colorectal distention. The abdominal contractions induced by colorectal distention at 30 mm Hg were counted for 10 min before and 1 h after acetic acid treatment. In the second series of experiments, the effects of TAK-637 and the various reference drugs on viscerosensory response were investigated. The inhibition rate for each drug (percentage) was calculated by comparing the number of contractions induced by the combined acetic acid/colorectal distention procedure before and after administration of each drug; namely, 1 h after administration of acetic acid solution into the colorectum, the colorectum was distended. At this time, the most appropriate distention pressure was selected as described above. The animals showing different distention pressure responses were assigned evenly to each group so that the mean distention pressure was the same among the treatment groups. A 10-min interval was taken between each distention period. TAK-637, the enantiomer of TAK-637, trimebutine maleate, ondansetron, atropine sulfate, and buprenorphine hydrochloride were administered intraduodenally 10 min after distention with the appropriate pressure (first distention). Forty minutes later, the colorectum was distended with the same pressure (second distention). In addition, (±)-CP-99,994 and buprenorphine hydrochloride were given i.v. 3 min before the second distention period. TAK-637 and M-I were given i.v. 10 min before the second distention period. Intrathecal injections of TAK-637 and (±)-CP-99,994 were performed 30 and 5 min before the second distention period, respectively. In the third series of experiments, we investigated the effect of TAK-637 on the viscerosensory response after administration once daily for 7 consecutive days to determine whether the inhibitory effect of TAK-637 is affected by repeated administration. The seventh dose was administered 40 min before the second distention period. The total number of animals used in these experiments was 150. In the first series of experiments, 11 animals were used. In the second and third series of experiments investigating the effects of various drugs on viscerosensory response, 5 animals were assigned to each group.Statistical Analysis. To compare the effects of the various drugs on the viscerosensory response, the inhibition rate (percentage) for each drug was calculated as follows: inhibition rate (%) = (1 - B/A) × 100; where A and B represent the number of abdominal contractions induced by colorectal distention before (A) and after (B) drug administration.
All data are expressed as the mean ± S.E.M. The statistical significance of differences among all the groups was determined using Dunnett's test, whereas differences between two particular groups were analyzed using the paired or Student's t test.| |
Results |
|---|
|
|
|---|
Acetic Acid Solution-Induced Colorectal Irritation.
To
determine whether 0.8% acetic acid solution induces hypersensitivity
in the colorectum, the number of abdominal contractions caused by
colorectal distention was counted before and after the administration
of acetic acid solution. One hour after the intracolorectal administration of acetic acid solution, the number of
distention-induced abdominal contractions showed a significant 4-fold
increase (Fig. 1). Because the visceral
sensitizing effect of acetic acid treatment remained apparent for at
least 4 h, the effects of TAK-637 and the other reference drugs
were investigated under this condition.
|
Effects of Tachykinin NK1 Receptor Antagonists and
Reference Drugs on the Viscerosensory Response.
In acetic
acid-treated rabbits, the number of abdominal contractions caused by
colorectal distention was slightly increased after vehicle
administration. Intraduodenal administration of TAK-637
dose-dependently inhibited the viscerosensory response to colorectal
distention in rabbits (Fig. 2). A
significant inhibitory effect was observed with doses of 0.3 to 3 mg/kg, and the inhibition rate at a dose of 1 mg/kg, intraduodenally,
was 48.6 ± 7.1% (n = 5). Another tachykinin
NK1 receptor antagonist, (±)-CP-99,994, also
inhibited the abdominal response dose dependently and significantly when given i.v. (Fig. 3). By contrast,
the enantiomer of TAK-637, which possesses only about 1/750 of the
affinity for tachykinin NK1 receptors shown by
TAK-637, had no effect on the abdominal contractions. The inhibition
rates for the vehicle alone and the enantiomer at a dose of 3 mg/kg,
intraduodenally were 1.0 ± 9.0 and
2.5 ± 10.8%
(n = 5), respectively.
|
|
|
Effects of TAK-637 and M-I on the Viscerosensory Response.
To
clarify whether TAK-637 inhibits the viscerosensory response by acting
peripherally or centrally, we investigated the effect of its main
metabolite, M-I, which has more potent tachykinin NK1 receptor antagonistic activity but is mainly
distributed to the peripheral organs, on colorectal distention.
Intravenous injection of TAK-637 dose dependently and significantly
reduced the number of abdominal contractions in the rabbits (Fig.
5). Although M-I also inhibited the
abdominal response, its inhibitory effect was less than that of TAK-637
(Fig. 5).
|
Effects of Intrathecal Administration of Tachykinin NK1
Receptor Antagonists on the Viscerosensory Response.
To clarify
whether TAK-637 acts at the spinal level, the effect of i.t.
administration on the viscerosensory response was investigated. At a
dose of 10 µg i.t., TAK-637 significantly inhibited the
viscerosensory response caused by colorectal distention in acetic
acid-treated rabbits by 62.7 ± 12.6% (n = 5;
Fig. 6A). (±)-CP-99,994 at a dose of 10 µg, i.t. also significantly inhibited the abdominal response caused
by colorectal distention (n = 5; Fig. 6B).
|
| |
Discussion |
|---|
|
|
|---|
It is well known that, in both humans and experimental animals,
distention of the gastrointestinal tract elicits abdominal pain,
thereby inducing pseudaffective reflexes such as viscerosensory or
cardiovascular responses (Ness and Gebhart, 1988
). Abdominal contractions induced by colorectal distention in rats have been used to
quantify visceral perception and to assess therapeutic agents for
functional bowel disorders such as IBS (Langlois et al., 1997
). Because
this response is attenuated by morphine, colorectal distention seems to
act as a nociceptive stimulus to organs, leading to abdominal
contractions (Ness and Gebhart, 1988
). Furthermore, the abdominal
response to colorectal distention in rats is abolished after
spinalization but not by decerebration, suggesting that distention acts
via brainstem loops (Ness and Gebhart, 1990
).
The mean sensory thresholds of hollow organs are generally lower in IBS
patients than in unaffected individuals (Mertz et al., 1995
). Although
the mechanism underlying this hypersensitivity is not fully understood,
previous infection, inflammation, and/or psychological stress have been
associated with the bowel dysfunction observed in IBS (Gwee et al.,
1996
; Accarino et al., 1997
). Langlois et al. (1997)
found that
colorectal hypersensitivity could be induced by intracolorectal
treatment with 0.6% acetic acid solution in rats. In the present
study, we used 0.8% acetic acid solution to induce colorectal
hypersensitivity. Our preliminary histological study revealed areas of
slight detachment of the epithelium and neutrophilic invasion, but no
hemorrhage, in colorectal segments treated with 0.8% acetic acid
solution (data not shown). The number of abdominal contractions caused
by colorectal distention was markedly increased after treatment with
0.8% acetic acid in rabbits as well as in rats. Buprenorphine, an
analgesic, markedly inhibited the abdominal response caused by
colorectal distention of the irritated colon, indicating that this
response was caused by noxious stimuli. In addition, Plourde et al.
(1997)
showed that this colorectal hypersensitivity was attenuated by
treatment with a large dose of capsaicin in rats, suggesting that this
response is, at least in part, mediated via capsaicin-sensitive
afferent C-fibers.
In the present study, the tachykinin NK1 receptor
antagonist TAK-637 dose dependently inhibited the viscerosensory
response in rabbits, and repeated administration did not decrease this inhibitory effect. (±)-CP-99,994, another tachykinin
NK1 receptor antagonist that differs structurally
from TAK-637, also inhibited the abdominal response in a dose-dependent
manner. On the other hand, the enantiomer of TAK-637, which has only
about 1/750 of the tachykinin NK1 receptor
antagonistic activity of TAK-637 (Natsugari et al., 1999
), did not
inhibit the abdominal contractions. The first main points of this study
are, therefore, that tachykinin NK1 receptor
antagonists exert a potent inhibitory effect on the viscerosensory
response, and that TAK-637 inhibited the response specifically via
tachykinin NK1 receptors. Moreover, in our
preliminary study, TAK-637 did not change colorectal compliance in
rabbits (data not shown). McLean et al. (1998)
and Pan et al. (1995)
have also shown that tachykinin NK1 receptor
antagonists inhibit nociceptive reflex responses to jejunal distention
in rats and gallbladder distention in cats. These results clearly show
that tachykinin NK1 receptors play an important
role in visceral perception.
Numerous studies of the distribution of tachykinin
NK1 receptors have shown that, although there are
differences among species, tachykinin NK1
receptors are widely distributed throughout the central and peripheral
nervous systems. In the gastrointestinal tracts of rodents, SP is
located in SP-containing neurons found almost entirely in the Auerbach
and Meissener enteric nervous systems (Holzer and Holzer-Petsche,
1997
). Moreover, the sensory afferent neurons known as
capsaicin-sensitive C-fibers, which run from the viscera to the spinal
dorsal root ganglia, also contain SP (Gamse et al., 1980
). The
terminals of these C-fibers are known to be located mainly in
superficial laminae I of the spinal cord, and SP is one of the most
abundant peptides in this region (Todd and Spike, 1993
). In somatic
pain models, the expression of SP in the spinal cord is increased by
arthritis-induced hyperalgesia (Walker et al., 2000
). Moreover, after
i.t. administration, SP induced hyperalgesia to mechanical stimulation
in unanesthetized animals, whereas administration of anti-SP monoclonal
antibody by the same route diminished the pain responses caused by tail pinching and arthritis (Kuraishi et al., 1991
; Satoh et al., 1992
). Rupniak et al. (1996)
reported that the tachykinin
NK1 receptor antagonist L-733,060
((2S,3S)-3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenyl piperidine inhibited the late, but not the early, phase of the nociceptive behavior in gerbils elicited by intraplantar injection of
formalin. In the chemical visceral pain model, the pain response was
attenuated in preprotachykinin A-disrupted mice (Cao et al., 1998
), but
Zimmer et al. (1998)
and Laird et al. (2000)
reported that the pain
response did not change in tachykinin 1 gene-deleted mice or
tachykinin NK1 receptor knock-out mice. Although
the importance of SP or tachykinin NK1 receptors
in transmitting the somatic pain response and chemically induced
visceral pain response is controversial, there are several consistent
reports indicating the important role of spinal SP in
distention-induced visceral pain response. Tachykinin
NK1 receptor knock-out mice fail to develop a
hypersensitive response to colon distention after acetic acid
instillation, and they do not show hyperalgesia to inflammation of the
colon or bladder (Laird et al., 2000
). Martinez et al. (1998)
proposed
that colorectal distention induces the expression of a proto-oncogene,
c-fos, an indicator of activated neurons, in the lumbosacral
spinal cord. These findings suggest that SP in some part of the spinal
cord is involved in transmitting and amplifying pain stimuli from the
colorectum. In the present study, we therefore attempted to clarify
whether TAK-637 acts on spinal tachykinin NK1
receptors. TAK-637 is known to pass through the blood-brain barrier,
but it has not yet been determined whether it acts on peripheral nerves
and/or in the CNS. Intrathecal administration of TAK-637 and
(±)-CP-99,994 produced a marked inhibitory effect on abdominal
contractions, suggesting that spinal tachykinin
NK1 receptors are indeed involved in the visceral
reaction induced by colorectal distention. Although it is possible that
TAK-637 inhibited the viscerosensory response by acting peripherally, e.g., by reducing local inflammation after the acetic acid treatment or
inhibiting the transmission of afferent fibers innervating the
colorectum, the first possibility is unlikely. This is because in our
experiments, the tachykinin NK1 receptor
antagonists were administered after the animals had become
hypersensitive, and the time span between drug administration and the
second distention period was too short to allow inflammation to be
suppressed. Furthermore, i.v. administration of M-I, which is about
twice as potent an antagonist as TAK-637 and is distributed mainly in
the peripheral tissues (K. Iida and K. Onishi, unpublished
data), exhibited only a weak inhibitory effect on the
viscerosensory response in rabbits. Taken together, these results
strongly suggest that spinal tachykinin NK1
receptors are the main site of action of TAK-637, and that SP in the
spinal cord plays a pivotal role in mediating visceral perception.
Although both TAK-637 and (±)-CP-99,994 inhibited the viscerosensory
response caused by colorectal distention, their inhibitory effects
remained at about 50% even with high dosages. Therefore, it is
possible that receptors other than tachykinin NK1
receptors participate in this response. However, neither trimebutine
maleate, ondansetron, nor atropine sulfate attenuated abdominal
contractions in this study, indicating that peripheral opiate,
5-hydroxytryptamine3, and muscarinic receptors do
not participate in the viscerosensory response. These findings are in
agreement with those of previous studies (Poynard et al., 1994
; Maxton
et al., 1996
). Other candidate receptors known to be associated with
visceral pain are tachykinin NK2, calcitonin
gene-related peptide, and
N-methyl-D-aspartate receptors (McLean
et al., 1997
; Plourde et al., 1997
; Olivar and Laird, 1999
); however,
further studies will be required to clarify the involvement of these
receptors in the viscerosensory responses caused by colorectal
distention in rabbits.
It is known that chronic life stresses activate neural and hormonal
factors and can result in gastrointestinal dysfunction. In IBS
patients, stress seems to be strongly associated with the occurrence of
symptoms such as diarrhea, constipation, and abdominal pain, since
counseling therapy and anxiolytic or antidepressant agents are reported
to be effective treatments (Clouse, 1994
). The occurrence of IBS
symptoms is also known to be closely associated with the severity of
depression (Drossman, 1999
). Recently, Kramer et al. (1998)
reported
that a tachykinin NK1 receptor antagonist showed
antidepressant activity in experimental animals as well as in patients
with a major depressive disorder. Although there is no conclusive
evidence that TAK-637 has an anxiolytic effect, the possibility cannot
be ruled out because this agent permeates into the CNS. Furthermore,
TAK-637 has been found to inhibit restraint stress-induced defecation
in gerbils (Okano et al., 2001
). These results suggest that TAK-637 has
potential usefulness in the treatment of IBS.
In summary, our investigation has clearly shown that the tachykinin NK1 receptor antagonist TAK-637 inhibits the viscerosensory response induced by colorectal distention of the irritated colon in rabbits, and that its main site of action seems to be tachykinin NK1 receptors in the spinal cord. Taken together with the recent finding that TAK-637 inhibits stress-induced defecation in gerbils, our results indicate that TAK-637 could be a useful therapeutic agent for the treatment of functional bowel disorders such as IBS.
| |
Acknowledgments |
|---|
We thank K. Matsushita for technical collaboration.
| |
Footnotes |
|---|
Accepted for publication October 30, 2001.
Received for publication August 2, 2001.
Address correspondence to: Dr. Nobuhiro Inatomi, Pharmacology Research Laboratories II, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 2-17-85, Juso-Honmachi, Yodogawa-ku, Osaka 532-8686, Japan. E-mail: inatomi_nobuhiro{at}takeda.co.jp
| |
Abbreviations |
|---|
IBS, irritable bowel syndrome; NK, neurokinin; SP, substance P; CNS, central nervous system; TAK-637, (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione; M-I, metabolite I; (±)-CP-99,994, (±)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine; L-733,060, ((2S,3S)-3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Gaman, M. C. Bucur, and B. Kuo Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome Therapeutic Advances in Gastroenterology, May 1, 2009; 2(3): 169 - 181. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||